Morepen Laboratories Share News - Latest Updates, Live News & More

Latest news about Morepen Laboratories

Morepen Laboratories Q3FY26 Results: Net Profit Grows 3% YoY to ₹2750.93 Crores 5 days ago

Morepen Laboratories Limited reported Q3FY26 consolidated net profit of ₹2750.93 crores, up 3.07% YoY from ₹2668.85 crores. Total income grew 6.53% to ₹48796.66 crores. Nine-month performance showed net profit of ₹7913.22 crores versus ₹9770.50 crores in the previous year. The company underwent structural changes with Dr. Morepen Limited ceasing to be a subsidiary from July 31, 2025.

Morepen Laboratories Reports Status on Physical Share Transfer Re-lodgement Under SEBI Special Window Jan 28, 2026

Morepen Labs Secures High Court Stay on ₹117.94 Crore GST Show-Cause Notice Jan 09, 2026

Morepen Laboratories Secures Court Stay on ₹118 Crore Tax Demand Jan 09, 2026

Court Halts ₹1.18 Billion Tax Demand Against Morepen Laboratories Jan 08, 2026

More news about Morepen Laboratories

08Jan 26

Morepen Laboratories Secures High Court Stay on ₹117.94 Crore GST Show Cause Notice

Morepen Laboratories Limited has obtained a stay order from the Himachal Pradesh High Court on a ₹117.94 crore GST Show Cause Notice. The court order dated 6th January 2026 provides relief from the notice issued by Central GST Commissionerate, Shimla, which alleged excess GST refund claims under CGST Act provisions. The company confirms no financial or operational impact due to the favorable court decision.

04Dec 25

Morepen Laboratories Faces ₹117.94 Crore GST Refund Dispute

Morepen Laboratories has received a Show Cause Notice from GST authorities alleging erroneous refund claims of ₹117.94 crore for FY 2020-2024. The dispute centers on the company's method of applying for refunds of accumulated Input Tax Credit on zero-rated supply. Morepen denies wrongdoing and plans to submit supporting documents and seek legal advice. The disputed amount represents 6.63% of the company's total assets for FY 2025.

10Nov 25

Morepen Laboratories Secures Rs 50 Crore Unsecured Term Loan from Kookmin Bank

Morepen Laboratories' Finance Committee has approved an unsecured term loan of Rs 50 crore from Kookmin Bank for general corporate purposes. The loan has a 3-year tenure with an interest rate of prevailing repo rate plus 2.20% per annum. It includes a one-year moratorium and quarterly principal repayments. The company's total outstanding loan amount now stands at Rs 138.87 crore. The loan is secured by a personal guarantee from Mr. Sushil Suri, the Promoter and Chairman Managing Director.

08Sept 25

Morepen Medipath Forms 50:50 Joint Venture with UAE's Bimedical FZE for Medical Device Manufacturing

Morepen Laboratories' subsidiary, Morepen Medipath Limited (MML), has entered into a 50:50 joint venture agreement with UAE-based Bimedical FZE to form a new company focused on manufacturing, trading, and selling medical devices. MML will acquire 50% shareholding in the proposed JVC, while Morepen Laboratories will indirectly hold 30% through MML. The JVC will be incorporated in India, with both parties contributing equally to the share capital in cash. This strategic move aims to expand Morepen's presence in the medical devices market.

06Sept 25

Morepen Laboratories Holds 40th AGM, Approves Dividend and Key Appointments

Morepen Laboratories conducted its 40th AGM on September 6, 2025, via video conferencing. The company approved a final dividend of ₹0.20 per equity share for FY 2025. Shareholders adopted the audited financial statements and reappointed Sanjay Suri as a director. Dr. Savita was reappointed as an Independent Director, and Sanjay Suri as a Whole-Time Director. The AGM approved the extension for transferring the Medical Devices Business to Morepen Medipath Limited. New auditor appointments were made, and related party transactions for key management personnel relatives were approved. A special resolution allowing conversion of loans into shares was also passed.

13Aug 25

Morepen Laboratories Expands into Medical Devices with New Subsidiary

Morepen Laboratories Limited has incorporated a new step-down subsidiary, Sigmacheck Health Private Limited, to enter the medical devices industry. The subsidiary, approved on August 13, 2025, has an authorized and paid-up capital of ₹1,00,000. Morepen Laboratories holds a 60% indirect stake through its wholly-owned subsidiary, Morepen Medipath Limited. This strategic move aims to diversify Morepen's portfolio and capitalize on the growing healthcare equipment market.

06Aug 25

Morepen Laboratories Reports Q1 Results, Sets Dividend Record Date, and Approves Leadership Changes

Morepen Laboratories reported a decrease in Q1 net profit to Rs 1074.83 lakhs consolidated, down from Rs 3616.79 lakhs last year. The company set August 30 as the record date for final dividend distribution. Board decisions include re-appointing Sanjay Suri as Whole-Time Director and appointing M/s. PD and Associates as Secretarial Auditor. The company approved an extension for transferring its Medical Devices Business to subsidiary Morepen Medipath Limited. Shareholding in Dr. Morepen Limited decreased from 80% to 19.94%. The 40th AGM is scheduled for September 6 via video conferencing.

01Aug 25

Morepen Laboratories Reshapes Business Portfolio: Sells Stake in Dr. Morepen, Indirectly Acquires Groom Town

Morepen Laboratories has sold 1.53 crore equity shares of its subsidiary Dr. Morepen Limited (DML) for ₹30.65 crore, reducing its stake from 80% to 49.91%. DML will acquire Groom Town Private Limited for ₹153.01 crore, further diluting Morepen's stake to 19.94%. These moves aim to focus on Morepen's core API business and diversify into the FMCG space. The transactions were valued by independent registered valuers to ensure fair pricing.

25Jul 25

Morepen Laboratories Expands into Medical Devices with New Subsidiary SIGMACHECK HEALTH

Morepen Laboratories Limited has approved the formation of SIGMACHECK HEALTH PRIVATE LIMITED, a new step-down subsidiary focusing on medical devices. The subsidiary will be wholly owned by Morepen Medipath Limited, with Morepen Laboratories indirectly holding a 60% equity stake. Initial investment is set at Rs. 1,00,000 for 10,000 shares at Rs. 10 each. This strategic move aims to strengthen Morepen's presence in the medical devices sector and capitalize on growing market demands.

22Jul 25

Morepen Laboratories Expands Global Footprint with New Dubai Subsidiary

Morepen Laboratories has incorporated a new step-down subsidiary, MOREPEN MEDICAL EQUIPMENT TRADING L.L.C, in Dubai, UAE. The subsidiary, with an authorized capital of AED 100,000, is wholly owned by Morepen Medipath Limited and will focus on sales and marketing of medical devices in international markets, particularly Dubai and surrounding regions. This strategic move aims to enhance Morepen's global reach and strengthen its position in the medical equipment sector.

30Jun 25

Morepen Laboratories Reduces Stake in Morepen Medipath to 60%

Morepen Laboratories has decreased its ownership stake in its subsidiary, Morepen Medipath Ltd, to 60% following a new share issuance by the subsidiary. This move has resulted in a dilution of Morepen Laboratories' ownership in Morepen Medipath. The share issuance could indicate a strategy to raise additional capital for the subsidiary, potentially for expansion plans or strengthening its financial position.

12May 25

Morepen Laboratories Amends Business Transfer Agreement with Morepen Medipath

Morepen Laboratories Ltd. has executed an addendum to its existing Business Transfer Agreement with Morepen Medipath. This modification could potentially affect the scope of business transfer, financial terms, or operational arrangements between the two entities. The amendment suggests that Morepen Laboratories is adapting its business strategy to current market conditions or corporate objectives. While specific details of the addendum are not disclosed, this change may have implications for shareholders, employees, and business partners.

12May 25

Morepen Laboratories Reports Mixed Q4 Results: Revenue Up, Profits Down, Plans Dubai Subsidiary

Morepen Laboratories announced Q4 financial results with total income rising to ₹470.00 crore, up 11.11% year-over-year. However, net profit declined 31.03% to ₹20.00 crore, and EBITDA fell to ₹42.30 crore. Full-year FY25 net profit increased to ₹118.00 crore. The company declared a dividend of ₹0.20 per share and plans to establish a new subsidiary in Dubai.

29Apr 25

Morepen Laboratories Expands Global Footprint with Dubai Subsidiary, Management Reshuffle, and CDSCO Approval for Resmetirom Studies

Morepen Laboratories Limited is establishing a wholly-owned subsidiary in Dubai's Free Zone to enhance international operations. The company has promoted Kushal Suri to President – International Growth. Additionally, Morepen received CDSCO approval for bioequivalence studies of Resmetirom, a potential NASH treatment, positioning it among the first Indian companies ready for the drug's global launch.

28Apr 25

Morepen Laboratories Expands Global Footprint with New Dubai Subsidiary

Morepen Laboratories Limited plans to set up a wholly-owned subsidiary in Dubai, UAE, named Morepen Labs FZCO. The company will invest AED 50,000 (approx. INR 11.25 lakhs) as initial capital. The new entity will focus on sales and marketing of Morepen's products internationally. Additionally, Mr. Kushal Suri has been appointed as President of International Growth, effective April 28, 2025.

24Apr 25

Morepen Labs Launches New Products, Aims for Rs 1,000 Crore in Formulation Business

Morepen Laboratories introduced four new prescription products in April 2025, aiming to expand its formulation business from Rs 325 crore to Rs 1,000 crore over the next five years. This launch is part of the company's R&D-driven growth strategy in the pharmaceutical sector.

11Apr 25

Morepen Laboratories Unveils Ambitious Plan to Expand Salesforce by Over 1,000 Professionals

Morepen Laboratories plans to add over 1,000 professionals to its salesforce in the next three years, with 200 joining in FY26. This expansion aims to strengthen its domestic market presence and deepen connections with healthcare stakeholders. The company targets growing its ₹325 crore formulations business to ₹1,000 crore within five years. This strategy aligns with India's healthcare vision and the projected growth of the Indian pharmaceutical market to $130 billion by 2030.

01Apr 25

Morepen Laboratories Expands Global Reach: Secures Loratadine Approval for China Export

Morepen Laboratories has received approval from China's National Medical Products Administration to export Loratadine, an antihistamine API, to the Chinese market. The company commands over 80% market share in the US generics market for Loratadine and exports to 82 countries. Morepen has a manufacturing capacity of 144 metric tons of API annually and USFDA-approved facilities. Recently, its US subsidiary acquired shares in ICB International, Inc., and Dr. Morepen Limited transitioned from a wholly-owned subsidiary to a subsidiary with an 80% stake.

19Mar 25

Morepen Laboratories Finalizes Business Transfer Agreement with Subsidiary Morepen Medtech

Morepen Laboratories Ltd. has executed a Business Transfer Agreement with its subsidiary, Morepen Medtech Limited, to transfer its Medical Devices Business as a 'slump sale'. The agreement, signed on March 18, 2025, involves the hiving-off of the business to the subsidiary, in which Morepen Laboratories holds 80% equity. The transaction, approved by shareholders and compliant with regulatory requirements, is conducted on an arm's length basis. The final consideration is subject to adjustments based on closing terms.

18Mar 25

Morepen Laboratories Finalizes Business Transfer Agreement with Subsidiary Morepen Medtech

Morepen Laboratories has executed a Business Transfer Agreement to transfer its Medical Devices Business to its subsidiary, Morepen Medtech Limited, as a 'slump sale'. The subsidiary is 80% owned by Morepen Laboratories, with the remaining 20% held by the promoter group and related entities. The transfer valuation will be based on Rule 11UAE of Income Tax Rules, 1962, with the final consideration subject to adjustments. This strategic move aims to streamline operations and enhance efficiency in both pharmaceutical and medical device sectors.

18Mar 25

Morepen Laboratories Unveils Empamore: A Game-Changer in Diabetes, Heart Failure, and Kidney Disease Treatment

Morepen Laboratories has introduced Empamore, a new treatment for Type 2 Diabetes Mellitus, Heart Failure, and Chronic Kidney Disease. Based on Empagliflozin, Empamore is priced 90% lower than existing brands, aiming to provide affordable access to quality treatment in India. The drug is manufactured in USFDA-approved facilities and comes in multiple formulations. With India's growing diabetes market and Morepen's global presence in 82 countries, this launch could significantly impact both patient care and the company's market position.